about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesPoly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerFunction of BRCA1 in the DNA damage response is mediated by ADP-ribosylationTranscriptional regulation of BRCA1 expression by a metabolic switchStructural basis for recruitment of BRCA2 by PALB2Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersDown-regulation of UCRP and UBE2L6 in BRCA2 knocked-down human breast cellsUnderstanding and treating triple-negative breast cancerSusceptibility pathways in Fanconi's anemia and breast cancerBRCAness: finding the Achilles heel in ovarian cancerProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerMicroRNA-182-5p targets a network of genes involved in DNA repairFOXM1 confers acquired cisplatin resistance in breast cancer cellsHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsThe biological effects and clinical implications of BRCA mutations: where do we go from here?Trial watch - inhibiting PARP enzymes for anticancer therapyOvarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for PreventionRole of Biomarkers in the Development of PARP InhibitorsThe clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancerBiomarkers in triple negative breast cancer: A reviewThe fate of chemoresistance in triple negative breast cancer (TNBC)DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeted Therapies in Triple-Negative Breast CancerTriple negative breast cancer: looking for the missing link between biology and treatmentsOlaparib in the management of ovarian cancerPARP inhibitors in the management of breast cancer: current data and future prospectsTargeting triple-negative breast cancer: optimising therapeutic outcomesNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionOncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discoveryBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsGenomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersEpidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestryTargeting DNA damage response in cancer therapyPARP inhibitors and morePARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesDiscovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2 H )-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 InhibitorsTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyCancer's Achilles' Heel: Apoptosis and Necroptosis to the RescueUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
P2860
Q21129302-CFD9798E-992A-47F3-BCC1-F60145500C39Q24187899-D3A8FF0C-D91D-4C35-AB38-059316BB5496Q24293084-28BAC190-D71F-4628-8BBC-607D560A85C5Q24307973-C81AEC53-4C39-43DA-9B19-4A6D1B76125BQ24315745-A25BAD1C-A4A0-4A68-932C-9AB177456E23Q24595138-226B660C-0754-476D-AA93-BF23006A62D9Q24600350-68CE3F53-ADE5-44C8-8635-CF473198F8F5Q24603819-9DA35F8F-D827-453C-9EB9-C75920CCB861Q24620957-59340D95-ED99-4E5F-8449-6CD30860B2C1Q24628760-D19C1931-5A2D-4AB9-BB6E-8566B2EE8993Q24630872-5E9A1421-8201-4781-999B-2C05F61C4A3EQ24632628-20F85582-068E-47CB-B446-3F023F03F0B2Q24633326-8115136D-03AB-4140-B5AA-5AD62E0958C9Q24642596-50FEBA05-9BE8-47A9-BDDB-DCD979B3E1D5Q24644255-20B74EB2-9C39-4E08-88D6-9145912D06C8Q26741851-EB640D50-663B-469E-AB66-B25046053178Q26745673-385E0D5B-2604-41F1-9C52-D47FCD341DDDQ26747279-A9BFB47F-DA68-41B3-A6E6-99BB44A6777EQ26753159-D4AD23D9-2E0A-4AAC-A60A-E23EE61080F3Q26766285-7BAC4CDB-2842-4DBA-9019-F3CC1AFA28BAQ26775094-F259ABFD-C84A-4E09-8DCE-610AED19F5EEQ26775232-FB916886-D84B-4EB2-AB89-B007C979E87DQ26776513-DC1DD693-04D6-458E-926F-041ECBAC508DQ26777736-9B5F83AF-32A9-4102-A0D3-90945C91DD72Q26783122-98CFD710-9C84-4558-A595-EEDD6405A326Q26797166-E4580645-B710-4923-B52B-EC9BD5ED393EQ26798352-A424362E-2FC0-4E97-8362-53E3B6161CE1Q26850892-CBEB666A-E46E-4361-B97E-09A66F31CD5AQ26851765-5F5A04FD-6A61-42D6-BA87-FA0A34BAACA0Q26851813-2185FB17-7095-46E7-8B85-5B4A8BBE7939Q26852274-287D08F7-D7F2-4560-B0B7-F1BC55009F55Q27006938-A925CF57-720A-4366-81A5-7E851BC3AD8DQ27011535-E0026118-BCEF-4C4C-8C90-43B9E67C5F71Q27023204-32BB6E75-02B9-470D-8F51-7B2C90F266B2Q27027014-F3A8FBF5-8E15-44DC-B408-0260BB7321BBQ27027503-B23E4252-A931-4359-8C3E-10365DBC7475Q27684311-97918C78-6A29-4833-BB82-696AA7508E67Q27860519-A7172F9D-FCF6-4901-B1D1-5B7827E37128Q28066868-14D77123-48CD-43DF-9990-C4D97A3633F0Q28071541-838E471D-5FC8-4AF0-ADAC-E10513303731
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Hallmarks of 'BRCAness' in sporadic cancers
@ast
Hallmarks of 'BRCAness' in sporadic cancers
@en
type
label
Hallmarks of 'BRCAness' in sporadic cancers
@ast
Hallmarks of 'BRCAness' in sporadic cancers
@en
prefLabel
Hallmarks of 'BRCAness' in sporadic cancers
@ast
Hallmarks of 'BRCAness' in sporadic cancers
@en
P2093
P2860
P3181
P356
P1476
Hallmarks of 'BRCAness' in sporadic cancers
@en
P2093
P2860
P2888
P3181
P356
10.1038/NRC1457
P407
P577
2004-10-01T00:00:00Z
P5875
P6179
1042257134